What we are studying
The purpose of this study is to compare any good and bad effects of using a combination of lenalidomide, ixazomib, dexamethasone and zoledronic acid along with the radiation therapy to using radiation therapy and zoledronic acid alone. The addition of lenalidomide, ixazomib, dexamethasone and zoledronic acid to the usual radiation could prevent it from returning but it could also cause side effects.
This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. The cancer drugs lenalidomide, dexamethasone, and zoledronic acid are approved by the FDA for use in multiple myeloma but not for this disease. Ixazomib is not FDA approved and is experimental.
Parking will be validated for all study related visits.